BRPI1011818A2 - "método de tratamento de câncer com antagonista de dll4 e agente quimioterapêutico" - Google Patents

"método de tratamento de câncer com antagonista de dll4 e agente quimioterapêutico"

Info

Publication number
BRPI1011818A2
BRPI1011818A2 BRPI1011818A BRPI1011818A BRPI1011818A2 BR PI1011818 A2 BRPI1011818 A2 BR PI1011818A2 BR PI1011818 A BRPI1011818 A BR PI1011818A BR PI1011818 A BRPI1011818 A BR PI1011818A BR PI1011818 A2 BRPI1011818 A2 BR PI1011818A2
Authority
BR
Brazil
Prior art keywords
chemotherapeutic agent
treating cancer
dll4 antagonist
dll4
antagonist
Prior art date
Application number
BRPI1011818A
Other languages
English (en)
Inventor
Alain Thibault
Gavin Thurston
Irene Noguera-Troise
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI1011818A2 publication Critical patent/BRPI1011818A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1011818A 2009-06-25 2010-06-25 "método de tratamento de câncer com antagonista de dll4 e agente quimioterapêutico" BRPI1011818A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22046509P 2009-06-25 2009-06-25
US30188110P 2010-02-05 2010-02-05
PCT/US2010/039999 WO2010151770A1 (en) 2009-06-25 2010-06-25 Method of treating cancer with dll4 antagonist and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
BRPI1011818A2 true BRPI1011818A2 (pt) 2016-03-29

Family

ID=42668243

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011818A BRPI1011818A2 (pt) 2009-06-25 2010-06-25 "método de tratamento de câncer com antagonista de dll4 e agente quimioterapêutico"

Country Status (27)

Country Link
US (3) US8518887B2 (pt)
EP (1) EP2445528B1 (pt)
JP (2) JP6038650B2 (pt)
KR (1) KR101750723B1 (pt)
CN (1) CN102481365A (pt)
AR (1) AR077241A1 (pt)
AU (1) AU2010266004B2 (pt)
BR (1) BRPI1011818A2 (pt)
CA (1) CA2766163C (pt)
DK (1) DK2445528T3 (pt)
ES (1) ES2556804T3 (pt)
HR (1) HRP20160045T1 (pt)
HU (1) HUE026356T2 (pt)
IL (1) IL216952A (pt)
ME (1) ME02296B (pt)
MX (1) MX2011013424A (pt)
MY (1) MY173234A (pt)
PL (1) PL2445528T3 (pt)
PT (1) PT2445528E (pt)
RS (1) RS54477B1 (pt)
RU (1) RU2571220C2 (pt)
SG (2) SG176791A1 (pt)
SI (1) SI2445528T1 (pt)
SM (1) SMT201500315B (pt)
TW (1) TWI513465B (pt)
UY (1) UY32739A (pt)
WO (1) WO2010151770A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
WO2012092539A2 (en) * 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
WO2014043484A2 (en) * 2012-09-13 2014-03-20 Thomas Jefferson University Metabolic remodeling of the tumor microenvironment: migration stimulating factor (msf) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth
US9599620B2 (en) * 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
AR093445A1 (es) * 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP3125919A4 (en) * 2014-02-19 2018-01-03 Microconstants China Inc. Chemokine receptor antagonist and its combinational therapy
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
US11291630B2 (en) * 2015-09-16 2022-04-05 Centre National De La Recherche Scientifique (Cnrs) Gelling compositions for treating malignant tumours and/or preventing tumour recurrence
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
CN110339350A (zh) 2019-07-25 2019-10-18 广州中科蓝华生物科技有限公司 一种抗肿瘤的联合用药物组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
PL366307A1 (en) 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
DE602004029581D1 (de) 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
JP2009507796A (ja) 2005-09-01 2009-02-26 バスジーン セラピューティクス， インコーポレイテッド デルタ様リガンド４のモジュレーターの利用及び同定方法
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
CA2630839C (en) * 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
NZ593226A (en) * 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
NZ572177A (en) 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
EP2029159A2 (en) 2006-06-06 2009-03-04 Genentech, Inc. Compositions and methods for modulating vascular development
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JP2010517944A (ja) * 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー Ｄｌｌ４シグナリング阻害薬およびその使用
EP1958632A1 (en) * 2007-02-14 2008-08-20 Dan Stoicescu Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases
AU2009294415B2 (en) * 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法

Also Published As

Publication number Publication date
EP2445528A1 (en) 2012-05-02
AU2010266004B2 (en) 2014-11-27
AU2010266004A1 (en) 2012-01-19
JP6038650B2 (ja) 2016-12-07
TW201113036A (en) 2011-04-16
TWI513465B (zh) 2015-12-21
DK2445528T3 (en) 2016-01-18
IL216952A0 (en) 2012-02-29
US8840886B2 (en) 2014-09-23
RS54477B1 (sr) 2016-06-30
SG10201403568RA (en) 2014-10-30
WO2010151770A1 (en) 2010-12-29
SMT201500315B (it) 2016-01-08
MY173234A (en) 2020-01-07
MX2011013424A (es) 2012-02-23
US20100330106A1 (en) 2010-12-30
HUE026356T2 (en) 2016-06-28
US20150064189A1 (en) 2015-03-05
IL216952A (en) 2016-11-30
HRP20160045T1 (hr) 2016-02-12
SG176791A1 (en) 2012-01-30
US8518887B2 (en) 2013-08-27
CA2766163A1 (en) 2010-12-29
KR101750723B1 (ko) 2017-06-27
CN102481365A (zh) 2012-05-30
AU2010266004A8 (en) 2014-12-18
JP2016006101A (ja) 2016-01-14
AR077241A1 (es) 2011-08-10
RU2012102415A (ru) 2013-07-27
ME02296B (me) 2016-02-20
RU2571220C2 (ru) 2015-12-20
ES2556804T3 (es) 2016-01-20
PT2445528E (pt) 2016-01-26
SI2445528T1 (sl) 2016-04-29
JP2012531437A (ja) 2012-12-10
US20130302356A1 (en) 2013-11-14
PL2445528T3 (pl) 2016-03-31
KR20120102577A (ko) 2012-09-18
HK1169328A1 (en) 2013-01-25
EP2445528B1 (en) 2015-10-14
UY32739A (es) 2011-01-31
CA2766163C (en) 2018-01-02

Similar Documents

Publication Publication Date Title
BRPI1011818A2 (pt) "método de tratamento de câncer com antagonista de dll4 e agente quimioterapêutico"
EP2434891A4 (en) METHOD FOR THE TREATMENT OF CANCER AND NOT NEOPLASTIC ILLNESS STATES
EP2276509A4 (en) PROOF AND TREATMENT OF PANCREAS, EGGS AND OTHER CARCINOMAS
IL213070A0 (en) Methods for the treatment of infections and tumors
BR112012004149A2 (pt) terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
PT2365802T (pt) Microcápsulas de rapamicina e utilização para o tratamento de cancro
PL2483278T3 (pl) Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu
EP2499486A4 (en) COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
EP2142213A4 (en) METHOD FOR INHIBITING COMPLEMENTATION ACTIVATION WITH HUMAN ANTI-FACTOR C3 ANTIBODIES AND THEIR USE
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
EP2310526A4 (en) COMPOSITIONS FOR THE DETECTION AND TREATMENT OF COLORECTAL CARCINOMAS
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
BRPI1008717A2 (pt) artigos e métodos de tratar condições vasculares.
BRPI0819361A2 (pt) Composição de tratamento de cabelos e agente de tratamento
IL207360A0 (en) Methods of diagnosing and treating parp - mediated diseases
ZA200904806B (en) Prevention and treatment of sub-clinical pcvd
EP2242854A4 (en) COMPOUNDS AND USES THEREOF
IL207631A0 (en) Postsynaptically targeted chemodenervation agents and their methods of use
ES2614941T8 (es) Dispositivo de agente de revestimiento y dispositivo de revestimiento
EP2189537A4 (en) DETECTION AND TREATMENT OF SCHIZOPHRENIA
BR112014012495A2 (pt) método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer
IL206891A0 (en) Therapeutic inhibitors of pai-1 function and methods of their use
EP2012798A4 (en) USE OF INOSITOL-TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2521 DE 30-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.